评《系统性硬化症临床路径》

Evaluation of the Systemic Sclerosis Clinical Pathway

目的规范皮肤病临床路径。方法评论《系统性硬化症临床路径》。结果存在病与症,全身性和系统性之别,应统一为一种名称,青霉胺治疗硬皮病不当。结论系统性硬化症名称有待商榷,建议取消青霉胺。

Objective Regulate skin disease clinical pathway. Methods Comment on the systemic sclerosis clinical pathway. Results There is illness and disease, systemic and systematic, should be unified as a name, im-proper penicillamine treatment of scleroderma. Conclusion Systemic sclerosis name is up for debate, the proposal cancel penicillamine.